Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

about

Preprocedural Mean Platelet Volume Level Is a Predictor of In-Stent Restenosis of the Superficial Femoral Artery Stents in Follow-Up.

P2860

Q54956605-EF305AC2-6978-4675-AA83-612D9F3F2EDE

P2860

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

Item

http://www.wikidata.org/entity/Q53816466

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

@en

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

@nl

type

Item

label

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

@en

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

@nl

prefLabel

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

@en

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

@nl

P1476

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

@en

P2093

Kenji Ando

http://www.w3.org/2001/XMLSchema#string

Masahiko Fujihara

http://www.w3.org/2001/XMLSchema#string

Osamu Iida

http://www.w3.org/2001/XMLSchema#string

Yoshimitsu Soga

http://www.w3.org/2001/XMLSchema#string

Yusuke Tomoi

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC)

Coronary stent restenosis in patients treated with cilostazol

A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis.

Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK.

Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients.

Cilostazol is associated with improved outcomes after peripheral endovascular interventions.

Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial.

National trends in lower extremity bypass surgery, endovascular interventions, and major amputations.

Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.

Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.

P304

640-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1526602817719284

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28675951

http://www.w3.org/2001/XMLSchema#string

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

about

P2860

P2860

Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698